-58%

est. 2Y upside i

Climate TechSeries A

Stage: early. Country: Denmark

Rank

#1121

Sector

Climate Tech, Biomanufacturing, Green Chemicals

Est. Liquidity

~4Y

Data Quality

Data: Medium

Again presents a moderate upside opportunity for a job seeker, with an estimated 80.5% expected equity upside over a 2-year horizon.

Last updated: March 10, 2026

Bull (35%)+250%

Again's proprietary AI-designed biocatalysts and modular biomanufacturing process achieve rapid commercial scale-up with the TXS-1 facility, securing additional large-scale partnerships beyond Dow and HELM AG. This drives revenue significantly above projections, justifying a $1.75B+ valuation by 2028, a 3.5x increase from the current estimated $500M.

Base (25%)+100%

Again successfully deploys its technology in key industrial facilities, steadily growing its customer base and product lines (acetate, acetic acid). While facing competition from well-funded players like Twelve, Again maintains its niche and grows to a $1B valuation by 2029, doubling the current estimated valuation.

Bear (40%)-80%

Scaling challenges for the biomanufacturing process or intense competition from incumbents and well-funded rivals like Twelve and LanzaTech lead to slower-than-expected market penetration and revenue growth. This results in a down round or an exit at a significantly reduced valuation of $100M or less, wiping out most common stock value due to $100M in liquidation preferences.

Est. time to liquidity~3.5 years

Preference Stack Risk

high

Investors hold $100M in liquidation preferences, which would be paid out before common stock in an exit at or below the estimated $500M valuation.

Dilution Risk

high

As an early-stage, capital-intensive company, Again is highly likely to require multiple future funding rounds, leading to further dilution for existing equity holders.

Secondary Liquidity

none

No information suggests an active secondary market or tender offers for Again's private shares.

Questions to Ask at the Interview

Strategic questions based on again's data — designed to show you've done your homework.

  • 1

    “Given the 'Later Stage VC' round in October 2025, how is Again thinking about its current valuation and runway, and what are the key commercial milestones for the next 12-18 months, particularly regarding the scale-up and revenue generation from TXS-1 and CPH-1?”

  • 2

    “With competitors like Twelve raising significant capital and achieving high valuations, how does Again plan to maintain its competitive advantage and capture market share in the rapidly evolving carbon utilization space, especially concerning product diversification beyond acetate and acetic acid?”

  • 3

    “Considering the high capital intensity of biomanufacturing and the current preference stack, what is the company's strategy for future funding rounds and potential liquidity events to ensure meaningful returns for common stock holders, and what is the expected timeline for such events?”

Community

Valuation Sentiment

Our model estimates -58% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.